Pallavi Singh Chauhan, Dhananjay Yadav*, Bhupendra Koul, Yugal Kishore Mohanta and Jun-O Jin* Pages 1144 - 1151 ( 8 )
A amyloid-β (Aβ) plaque formation in the brain is known to be the root cause of Alzheimer’s disease (AD), which affects the behavior, memory, and cognitive ability in humans. The brain starts undergoing changes several years before the actual appearance of the symptoms. Nanotechnology could prove to be an alternative strategy for treating the disease effectively. It encompasses the diagnosis as well as the therapeutic aspect using validated biomarkers and nano-based drug delivery systems, respectively. A nano-based therapy may provide an alternate strategy, wherein one targets the protofibrillar amyloid-β (Aβ) structures, and this is followed by their disaggregation as random coils. Conventional/routine drug therapies are inefficient in crossing the blood-brain barrier; however, this hurdle can be overcome with the aid of nanoparticles. The present review highlights the various challenges in the diagnosis and treatment of AD. Meticulous and collaborative research using nanotherapeutic systems could provide remarkable breakthroughs in the early-stage diagnosis and therapy of AD.
Amyloid-β, alzheimer`s, nanoparticles, drug delivery system, drug therapy, diagnosis, neurodegeneration.
Amity Institute of Biotechnology, Amity University Madhya Pradesh, Gwalior, 474005, Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara-144411, Punjab, Biochemistry Laboratory, Department of Botany, North Orissa University Baripada- 757003, Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541